HL
Harding Loevner’s Regeneron Pharmaceuticals REGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-11
| Closed | -$8K | – | 140 |
|
|
2022
Q3 | $8K | Buy |
+11
| New | +$8K | ﹤0.01% | 158 |
|
|
2021
Q3 | – | Sell |
-11
| Closed | -$6K | – | 160 |
|
|
2021
Q2 | $6K | Hold |
11
| – | – | ﹤0.01% | 150 |
|
|
2021
Q1 | $5K | Sell |
11
-15
| -58% | -$6.82K | ﹤0.01% | 153 |
|
|
2020
Q4 | $13K | Sell |
26
-2
| -7% | -$1K | ﹤0.01% | 139 |
|
|
2020
Q3 | $16K | Sell |
28
-1
| -3% | -$571 | ﹤0.01% | 163 |
|
|
2020
Q2 | $18K | Sell |
29
-16,718
| -100% | -$10.4M | ﹤0.01% | 122 |
|
|
2020
Q1 | $8.18M | Sell |
16,747
-590,595
| -97% | -$288M | 0.05% | 70 |
|
|
2019
Q4 | $228M | Sell |
607,342
-84,936
| -12% | -$31.9M | 1.01% | 33 |
|
|
2019
Q3 | $192M | Buy |
692,278
+2,858
| +0.4% | +$793K | 0.91% | 39 |
|
|
2019
Q2 | $216M | Sell |
689,420
-9,902
| -1% | -$3.1M | 0.99% | 33 |
|
|
2019
Q1 | $287M | Buy |
699,322
+18,591
| +3% | +$7.63M | 1.35% | 24 |
|
|
2018
Q4 | $254M | Buy |
680,731
+43,833
| +7% | +$16.4M | 1.47% | 24 |
|
|
2018
Q3 | $257M | Buy |
636,898
+18,259
| +3% | +$7.38M | 1.34% | 27 |
|
|
2018
Q2 | $213M | Sell |
618,639
-6,925
| -1% | -$2.39M | 1.2% | 29 |
|
|
2018
Q1 | $216M | Sell |
625,564
-6,347
| -1% | -$2.19M | 1.12% | 32 |
|
|
2017
Q4 | $238M | Sell |
631,911
-15,866
| -2% | -$5.96M | 1.35% | 27 |
|
|
2017
Q3 | $290M | Buy |
647,777
+116,195
| +22% | +$52M | 1.65% | 19 |
|
|
2017
Q2 | $261M | Sell |
531,582
-25,818
| -5% | -$12.7M | 1.6% | 21 |
|
|
2017
Q1 | $216M | Buy |
557,400
+242,162
| +77% | +$93.8M | 1.41% | 26 |
|
|
2016
Q4 | $116M | Sell |
315,238
-3,327
| -1% | -$1.22M | 0.81% | 48 |
|
|
2016
Q3 | $128M | Buy |
318,565
+152,425
| +92% | +$61.3M | 0.92% | 45 |
|
|
2016
Q2 | $58M | Buy |
+166,140
| New | +$58M | 0.45% | 59 |
|